Luspatercept
Reblozyl
Filters
Save & Share
Clear Filters
Location
Explore options near your center - or near your patient's home.
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Near Add Your Location
Accepting patients
ELEMENT-MDS
Phase 3 Clinical Trial Comparing Luspatercept VS Epoetin Alfa in Patients with Very Low – Intermediate Risk MDS Who Are Not Transfusion Dependent
Learn more- Erythroid Maturation Agent (EMA)
- Erythropoiesis-Stimulating Agent (ESA)
- Red Blood Cell Stimulant
- Phase 3
Accepting patients
A Phase 2, Single Arm Study of Luspatercept for the Treatment of Anemia in Lower Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Myelodysplastic Syndromes/ Myeloproliferative Neoplasms (MDS/MPN)
Learn more- Erythroid Maturation Agent (EMA)
- Red Blood Cell Stimulant
- Phase 2
Accepting patients
Luspatercept and Lenalidomide (L2)
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Learn more- Erythroid Maturation Agent (EMA)
- Immunomodulatory Drug
- Red Blood Cell Stimulant
- Phase 1/2
Accepting patients
MAXILUS
A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
Learn more- Erythroid Maturation Agent (EMA)
- Red Blood Cell Stimulant
- Phase 3
Accepting patients
Luspatercept for Lower Risk MDS
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
Learn more- Erythroid Maturation Agent (EMA)
- Red Blood Cell Stimulant
- Growth Factor
- Phase 2